Xtant Medical Holdings, Inc. (XTNT) AI Stock Analysis

Xtant Medical Holdings, Inc., headquartered in Belgrade, Montana, develops, manufactures, and distributes regenerative medicine products and medical devices for orthopedic and neurological surgeons globally. Its biomaterials portfolio includes OsteoSponge, a natural scaffold promoting cellular growth, along with OsteoSelect DBM Putty and OsteoSelect PLUS DBM Putty used as bone graft substitutes and void fillers. The company also provides 3Demin allografts, sports medicine ligament allografts, and milled spinal allografts. Furthermore, Xtant supports surgical interventions with spinal fixation systems, including Certex, Spider cervical plating, Axle interspinous fusion, and Xpress minimally invasive pedicle screw systems.

Between FY2021 and FY2025, annual revenue increased from $55.3M to $133.9M, representing a 5-year revenue CAGR of 20.2%. Gross margin widened from 58.8% in FY2021 to 62.9% in FY2025. Operating margin improved from -7.0% in FY2021 to 5.4% in FY2025, and net income turned from -$4.8M to positive $5.0M with diluted EPS of $0.04. However, recent performance slowed, with quarterly revenue falling 35.0% year-over-year in the latest quarter ended June 30, 2026. Over the trailing twelve months, revenue was $109.5M, operating margin stood at -18.1%, and diluted EPS was -$0.08.

As of June 30, 2026, Xtant held $9.9M in cash and short-term investments alongside total debt of $26.0M, resulting in net debt of $16.1M. Shareholders' equity was $40.0M, with a debt-to-equity ratio of 0.65 and a current ratio of 2.16. For FY2025, operating cash flow was $12.5M and free cash flow reached $10.2M. Capital expenditures totaled $2.4M and share buybacks were $65,000 in FY2025, while the share count rose 61.2% over the trailing 5-year period.

At $0.29 per share on October 16, 2026, Xtant had a market capitalization of $40.2M and an enterprise value of $68.7M. The stock traded at a price-to-sales multiple of 0.4x and an EV/EBITDA of 5.6x, compared to medians of 4.1x and 12.0x, respectively, for its US-listed Healthcare peers. Its forward P/E ratio was 34.8x, above the peer median of 17.3x. Over the past year, the stock fell 59.2%, underperforming the S&P 500 (SPY), which gained 16.8%.

Consensus coverage consists of 2 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $1.03, representing a 256.3% premium over the closing price of $0.29. For the fiscal year ending December 31, 2026, consensus estimates anticipate an EPS of -$0.08 on revenue of $99.4M. For FY2027, 3 analysts project revenue of $110.2M and an EPS of -$0.03. Xtant beat EPS expectations in 1 of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of Xtant Medical Holdings, Inc. (XTNT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: XTNT income statement, XTNT balance sheet, XTNT key metrics, XTNT analyst forecast, XTNT chart. See the XTNT stock overview for the latest quote and news.